Artiva Biotherapeutics, Inc. (ARTV) — 10-Q Filings

10-Q Filings (6)

• 10-Q Filing — May 8, 2026
• Artiva's Losses Widen Amid Soaring R&D Costs, Cash Dwindles — Nov 12, 2025 Risk: high
  Artiva Biotherapeutics, Inc. reported a net loss of $21.5 million for the three months ended September 30, 2025, an increase from a net loss of $17.5 million in
• Artiva's Q2 Loss Widens Amid Rising R&D Costs — Aug 6, 2025 Risk: high
  Artiva Biotherapeutics, Inc. reported a net loss of $24.7 million for the three months ended June 30, 2025, a significant increase from the $18.9 million net lo
• Artiva Biotherapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Artiva Biotherapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business oper
• Artiva Biotherapeutics Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Artiva Biotherapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its bus
• Artiva Biotherapeutics Files Q2 2024 10-Q — Aug 29, 2024 Risk: medium
  Artiva Biotherapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX